Latest News
Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story
Resolution Therapeutics Appoints Lisa Bright to its Board of Directors
London, 12 April 2021 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced the appointment of Lisa Bright as a Non-Executive Director of the Company.
Resolution: Fighting fibrosis with macrophages
Macrophages are emerging as one of the hottest tools in the fight against cancer, but Resolution is targeting a new application for the cells: attacking fibrosis.
Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd
Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced completion of a £26.6m Series A financing from Syncona Ltd (“Syncona”).